What is S2S Surgical?
S2S Surgical operates at the intersection of orthopedic innovation and minimally invasive surgical techniques. The company distinguishes itself through a specialized product suite, including the S2S Trigger Release System, the ECuTR ClearCision System, and the FaST CTR System. These proprietary platforms are engineered by experienced surgeons to prioritize soft tissue preservation, thereby reducing post-operative recovery times and enhancing overall patient outcomes. By providing direct, simplified access to pathological areas, S2S Surgical addresses critical inefficiencies in traditional surgical workflows, establishing a strong competitive moat in the orthopedic medical device market.
How much funding has S2S Surgical raised?
S2S Surgical has raised a total of $20K across 1 funding round:
Debt
$20K
Debt (2021): $20K with participation from PPP
Key Investors in S2S Surgical
PPP
Public-Private Partnership
What's next for S2S Surgical?
With the recent infusion of capital, S2S Surgical is poised to scale its operational footprint and broaden the clinical adoption of its minimally invasive systems. The strategic focus will likely shift toward expanding commercial distribution channels and investing in clinical validation studies to further solidify its market position. As the company transitions through this significant Series B/C stage, the emphasis remains on scaling manufacturing capabilities and fostering surgeon-led innovation to meet the rising demand for safer, more efficient surgical interventions in the upper extremity space.
See full S2S Surgical company page
